Cellectis and AstraZeneca have signed a strategic collaboration agreement that will see the latter investing $245 million into the former. That includes an upfront payment of $25 million and an equity purchase of up to $220 million.
The collaboration agreement has AstraZeneca planning to use Celletis’ proprietary gene editing technologies and manufacturing capabilities. It will use these for the development of novel cell and gene therapy candidates.
Under the terms of the agreement, Cellectis will see its research funded by AstraZeneca. It also covers options for milestone payments, as well as option fees for an investigational new drug (IND). Investors will note that its clinical-stage candidates, including UCART22, UCART123 and UCART20x22, will remain under its control.
André Choulika, PhD, CEO of Cellectis, said this about the news:
“This collaboration will allow us to leverage our pioneering research in gene editing and cell therapies, as well as our cutting-edge capabilities in manufacturing with the ambition to bring potentially life-saving therapies to patients with unmet medical need.”
CLLS Stock Movement Today
Following the collaboration announcement, shares of CLLS stock are seeing heavy trading today. As of this writing, more than 14 million shares have changed hands as traders buy more of the stock. For comparison, the company’s daily average trading volume is about 53,000 shares.
CLLS Stock is up 174.9% as of Wednesday morning.
Investors looking for more of the most recent stock market stories are in the right place!
We’re offering up insight into all of the hottest stock market news on Wednesday! That includes the biggest pre-market stock movers this morning, what’s going on with Cardio Diagnostics (NASDAQ:CDIO) stock and more. All of that news is ready to go down below!
More Wednesday Stock Market News
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
- Why Is Cardio Diagnostics (CDIO) Stock Up 45% Today?
- Why Is NIO Stock Down Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.